Warning: The NCBI web site requires JavaScript to function. more...
Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Lakhani SR, Khanna KK, Chenevix-Trench G.
Breast Cancer Res. 2010;12(2):104. Epub 2010 Mar 19.
Related citations
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.
Gorski JJ, Kennedy RD, Hosey AM, Harkin DP.
Clin Cancer Res. 2009 Mar 1;15(5):1514-8. Epub 2009 Feb 17. Review.
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.
Clin Cancer Res. 2004 Mar 15;10(6):2029-34.
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ.
Breast Cancer Res. 2010;12(1):R12. Epub 2010 Feb 11.
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G.
Clin Cancer Res. 2001 Jul;7(7):1937-45.
PML protein expression in hereditary and sporadic breast cancer.
Plevová P, Bouchal J, Fiurásková M, Foretová L, Navrátilová M, Zapletalová J, Curík R, Kubala O, Prokop J, Kolár Z.
Neoplasma. 2007;54(4):263-8.
Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
Roldán G, Delgado L, Musé IM.
Cancer Biol Ther. 2006 May;5(5):505-10. Epub 2006 May 13.
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Litwiniuk MM, Roznowski K, Filas V, Godlewski DD, Stawicka M, Kaleta R, Breborowicz J.
BMC Cancer. 2008 Apr 13;8:100.
Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
Lee EY.
Curr Opin Obstet Gynecol. 2008 Feb;20(1):68-73. Review.
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ.
Cancer Res. 1999 Apr 15;59(8):2011-7.
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.
Graeser M, Bosse K, Brosig M, Engel C, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer.
Virchows Arch. 2009 May;454(5):519-24. Epub 2009 Apr 21.
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
Honrado E, Benítez J, Palacios J.
Mod Pathol. 2005 Oct;18(10):1305-20. Review.
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J, Li R, Lu Y, Shupnik MA.
Oncogene. 2009 Jan 29;28(4):575-86. Epub 2008 Nov 10.
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H, Heinonen M, Heikkilä P, Kilpivaara O, Tamminen A, Aittomäki K, Blomqvist C, Ristimäki A, Nevanlinna H.
Breast Cancer Res. 2008;10(1):R17. Epub 2008 Feb 14.
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.
Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM.
Cancer Res. 2009 Feb 15;69(4):1273-8. Epub 2009 Feb 3.
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.
Oncogene. 2010 Jan 7;29(1):26-33. Epub 2009 Oct 5.
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Köstler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschläger M, Singer CF.
Endocr Relat Cancer. 2007 Dec;14(4):1053-62.
A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
Xu J, Watkins T, Reddy A, Reddy ES, Rao VN.
Int J Oncol. 2009 Apr;34(4):939-49.
BRCA1 expression and molecular alterations in familial breast cancer.
Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, Simone G, Schittulli F, Paradiso A.
Histol Histopathol. 2009 Jan;24(1):69-76.
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD.
Clin Cancer Res. 2005 Jun 1;11(11):4003-11.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on